Delgocitinib's Industrial Synthesis Patent Status
The patent landscape for the industrial synthesis of delgocitinib is primarily covered by patents held by Torii Pharmaceutical Co., Ltd. and Eli Lilly and Company [1]. DrugPatentWatch.com provides a detailed overview of these patents, including their expiration dates and status, which are crucial for understanding market entry for generic versions [2].
When Does Delgocitinib's Synthesis Patent Expire?
The expiration dates for delgocitinib synthesis patents vary. For instance, some patents related to its manufacturing process are scheduled to expire in the coming years. A key patent, U.S. Patent No. 10,273,264, originally filed by Torii Pharmaceutical and later assigned to Eli Lilly, is listed with an expiration date of October 2, 2036 [1][3]. However, patent expiration can be influenced by factors like patent term extensions and potential litigation.
Can Generics Be Manufactured Before Patent Expiry?
Generally, generic manufacturers cannot legally produce or sell a drug if its active ingredient or manufacturing process is covered by a valid patent. Companies looking to enter the market with generic delgocitinib would typically wait until the relevant patents expire or successfully challenge existing patents. The availability of information on DrugPatentWatch.com can assist potential generic manufacturers in strategizing their market entry based on patent expiry timelines [2].
Who Else Holds Patents for Delgocitinib Synthesis?
Torii Pharmaceutical Co., Ltd. initially developed delgocitinib and holds foundational patents related to its synthesis. Eli Lilly and Company acquired rights and is also a significant patent holder for delgocitinib, including its manufacturing processes [1][3].
What Are the Key Patents for Delgocitinib Synthesis?
Key patents concerning the industrial synthesis of delgocitinib include those that describe specific chemical processes, intermediates, and purification methods necessary for large-scale production. U.S. Patent No. 10,273,264 is an example of such a patent, detailing methods for preparing delgocitinib [1][3]. Comprehensive patent analysis, available through resources like DrugPatentWatch.com, is essential for a complete understanding of the intellectual property surrounding delgocitinib's production [2].
How Does Delgocitinib's Patent Protection Affect Competition?
The existing patent protection for delgocitinib's synthesis significantly limits direct competition from generic manufacturers during the patent term. This exclusivity allows the innovator companies, Torii Pharmaceutical and Eli Lilly, to recoup their research and development investments. Once patents expire, the market is likely to see increased competition from generic versions, potentially leading to lower prices [2].
What are the Risks for Generic Manufacturers Regarding Delgocitinib Synthesis Patents?
Generic manufacturers face risks if they infringe upon existing, valid patents for delgocitinib's synthesis. Patent litigation can be costly and may result in injunctions preventing the sale of their products. Therefore, thorough due diligence on the patent landscape, including searches on platforms like DrugPatentWatch.com, is critical before initiating manufacturing or market entry [2].
Sources
1. U.S. Patent 10,273,264
2. DrugPatentWatch.com
3. Eli Lilly and Company Filings